<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764513</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-PLAGH-BT-062</org_study_id>
    <nct_id>NCT04764513</nct_id>
  </id_info>
  <brief_title>Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT</brief_title>
  <official_title>Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT. A Dose Escalation, Open-label, Phase 1/2 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the infusion safety and potential curative properties of ex-vivo&#xD;
      expanded γδ T cells obtained from the same donor for patients who have hematological&#xD;
      malignancies and have accepted allogeneic hematopoietic stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of&#xD;
      ex-vivo expanded γδ T cell in patients with hematological malignancies after allogeneic&#xD;
      hematopoietic stem cell transplantation. γδ T cell will be separated from peripheral blood of&#xD;
      the same donors. After expansion in vitro, they will be infused to the patients as an&#xD;
      immunotherapy treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This dose escalation study will be conducted in two phases. The first phase will have 3 cohorts(Dose escalation, x5 dose increments between cohorts, 2×10^6、 1×10^7/kg and 5×10^7 of cells per kg of body weight). The second phase is an expansion cohort at the maximum tolerated dose determined in the first phase.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (AEs)[Safety]</measure>
    <time_frame>Day 28 after completion of treatment</time_frame>
    <description>Safety of γδ T cell assessed by incidence of treatment-emergent adverse events (AEs) per patient graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Dose-Limiting Toxicities (DLTs) [Tolerability]</measure>
    <time_frame>Day 28 after completion of treatment</time_frame>
    <description>Tolerability of γδ T cell assessed by incidence of dose-limiting toxicities (DLTs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients reaching Complete Remission (CR) [Efficacy]</measure>
    <time_frame>12 months post-treatment</time_frame>
    <description>Efficacy of ex-vivo expanded γδ T cell assessed by number of patients reaching Complete Remission (CR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) [Efficacy]</measure>
    <time_frame>12 months post-treatment</time_frame>
    <description>Efficacy of ex-vivo expanded γδ T cell assessed by overall survival (OS) measured in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>12 months post-treatment</time_frame>
    <description>Quality of life determined by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire 'C30'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of γδ T cell</measure>
    <time_frame>Before treatment and up to 3 months after treatment</time_frame>
    <description>Persistence of γδ T cell assessed by number in peripheral blood.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Patients with hematological malignancies after allo-HSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with negative minimal residual disease or stable disease:&#xD;
After inclusion, patients will receive or not receive chemotherapy. Subsequently, patients will be dosed with γδ T cell.&#xD;
Patients with positive minimal residual disease but not hematologic relapse:&#xD;
After inclusion, patients will receive chemotherapy. Subsequently, patients will be dosed with γδ T cell.&#xD;
Patients with hematologic relapse:&#xD;
After inclusion, patients will receive chemotherapy. Subsequently, patients will be dosed with γδ T cell.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ex-vivo expanded γδ T cell infusion</intervention_name>
    <description>Phase 1: Patients receive ex-vivo expanded γδ T cell (Dose escalation, 3 cohorts, x5 dose increments between cohorts, 2×10^6、 1×10^7 and 5×10^7 of cells per kg of body weight).&#xD;
Phase 2: Patients receive ex-vivo expanded γδ T cell at the maximum tolerated dose determined in Phase 1.</description>
    <arm_group_label>Patients with hematological malignancies after allo-HSCT</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with hematological malignancies after allogeneic hematopoietic stem cell&#xD;
             transplantation；&#xD;
&#xD;
          2. Age criteria: 18-65 years;&#xD;
&#xD;
          3. Weight criteria: &gt; 40kg;&#xD;
&#xD;
          4. Organ function criteria:&#xD;
&#xD;
             Cardiac function: Left ventricular ejection fraction (LVEF) ≥40%, Pulmonary function:&#xD;
             Indoor oxygen saturation≥95%, Alanine aminotransferase and aspartate aminotransferase&#xD;
             ≤ 2.5×ULN (upper limit of normal value), Total bilirubin ≤ 1.5×ULN, Serum creatinine ≤&#xD;
             1.5×ULN;&#xD;
&#xD;
          5. Life expectancy of at least 4 months;&#xD;
&#xD;
          6. ECOG (Eastern Cooperative Oncology Group) score ≤ 2;&#xD;
&#xD;
          7. Patients able to understand and sign written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. GVHD (graft versus host disease) ≥ grade Ⅱ；&#xD;
&#xD;
          2. Thrombotic microangiopathy；&#xD;
&#xD;
          3. Posttransplant lymphoproliferative disorders；&#xD;
&#xD;
          4. Uncontrolled infection or other uncontrolled medical or psychiatric disorders which&#xD;
             may preclude patients to undergo clinical studies (discretion of the attending&#xD;
             physician)；&#xD;
&#xD;
          5. Patients with chronic diseases that require treatment with immune agents or hormones;&#xD;
&#xD;
          6. Suffering from systemic autoimmune disease or immunodeficiency disease;&#xD;
&#xD;
          7. Systemic use of steroids;&#xD;
&#xD;
          8. Allergic constitution;&#xD;
&#xD;
          9. Hemorrhagic disease or coagulation disorders;&#xD;
&#xD;
         10. Patients participating in other clinical trials within 30 days prior to enrollment;&#xD;
&#xD;
         11. Patients receiving radiotherapy within 4 weeks prior to enrollment;&#xD;
&#xD;
         12. Pregnant or breastfeeding women;&#xD;
&#xD;
         13. According to the researcher's judgment, the patient has other unsuitable conditions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunji Gao, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Weidong Han, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Wei, Master</last_name>
    <phone>+86-13146682665</phone>
    <email>13146682665@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Wei, Master</last_name>
      <phone>+86-13146682665</phone>
      <email>13146682665@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Chunji Gao, Professor</last_name>
      <phone>+86-13911536256</phone>
      <email>gaochunji301@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Han weidong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

